4Q Revenues: $20.7 billion (+2%)
4Q Earnings: 4.0 billion (+32%)
FY Revenues: $82.1 billion (+1%)
FY Earnings: $15.1 billion (-1%)
Comments: Pharmaceutical sales were $10.5 billion in the quarter, up 4%. For the year pharmaceutical sales were $42.2 billion, up 4%. Growth for the year was driven by STELARA for the treatment of immune-mediated inflammatory diseases, DARZALEX for the treatment of multiple myeloma, IMBRUVICA for treating certain B-cell malignancies, TREMFYA for the treatment of moderate to severe plaque psoriasis, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA for the treatment of schizophrenia, and ERLEADA, a next-generation androgen receptor inhibitor for the treatment of prostate cancer. Growth was partially offset by biosimilar and generic competition, primarily declines in REMICADE, U.S. ZYTIGA and international VELCADE.
